NCT05201638Phase 3Active not recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Study sponsor: Immunic AG

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-11Estimated
Enrollment · participants1100Actual
Source updated2026-10-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 1050 participants (planned). After: 1100 participants (actual).

Primary completion date changed

Before: Oct 2024. After: Nov 2026.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source